The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000819325p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
21/05/2026
Date registered
Help: Date registered
8/07/2026
Date last updated
Help: Date last updated
8/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
8/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
REfractory VF InterVention with Esmolol- Australia - ‘REVIVE-AUS’
Scientific title
Esmolol in persistent ventricular fibrillation/tachycardia with de-emphasised adrenaline: A feasibility study in adults experiencing persistent ventricular fibrillation or tachycardia in out of hospital cardiac arrest (Australia)
Additional trial identifiers [1] 317356 0
Nil
Universal Trial Number (UTN)
U1111-1341-2463
Trial acronym
REVIVE-AUS
Related trial records

Health condition
Health condition(s) studied:
persistent shockable rhythm cardiac arrest 342017 0
Condition category
Condition code
Emergency medicine 338097 338097 0 0
Resuscitation
Cardiovascular 338098 338098 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure

Brief name: Esmolol-based intervention bundle with de-emphasised adrenaline and vector-change defibrillation ("Intervention Bundle")

Drug component

International Non-proprietary Name: Esmolol (esmolol hydrochloride)
Dose: 50 mg bolus, each dose followed by a 10 mL 0.9% sodium chloride flush
Maximum total dose during the study intervention window: 100 mg (two 50 mg boluses)
Mode of administration: Intravenous (IV) or intraosseous (IO) bolus
Schedule: Dose 1 immediately after randomisation to the intervention arm; Dose 2 administered if the patient remains in VF/VT 4 minutes after Dose 1
Duration of administration: A single 10-minute intervention window from the point of randomisation

Non-drug components of the bundle

Cessation of adrenaline – No further 1 mg adrenaline boluses are administered by the prehospital team during the 10-minute intervention window. If the patient achieves ROSC and subsequently re-arrests in VF/VT during the window, the second esmolol dose may be administered at the discretion of the treating clinicians; adrenaline remains withheld for the duration of the window.
Vector-change defibrillation – Defibrillation pads are repositioned to an anterior–posterior configuration after the three unsuccessful shocks that establish eligibility (if not already in this position). Vector change is included in both arms, consistent with current Australia and New Zealand Committee on Resuscitation (ANZCOR) guidance for persistent shockable rhythms, and is therefore not unique to the intervention arm; it is described here for completeness of the bundle as delivered.
Standard Advanced Life Support (ALS) continues throughout: high-quality manual or mechanical chest compressions (LUCAS 3 [Stryker] or Corpuls CPR [GS Elektromedizinische Geräte] where available), advanced airway management with waveform capnography, IV/IO access, amiodarone per ANZCOR ALS, and ongoing rhythm checks and defibrillation at standard 2-minute intervals.
Reversion to standard ALS – If the patient remains in persistent VF/VT 10 minutes after randomisation (i.e. after 5 cycles and 2 esmolol doses), the treating team reverts to standard ALS and may employ any further measures within their routine scope of practice, including transport to hospital. In-hospital management is at the discretion of the receiving team and is not constrained by the study protocol; beta-blockade in hospital is permitted if clinically indicated.

Materials used in intervention delivery

Pre-prepared esmolol 50 mg ampoules (or equivalent presentation) carried on Intensive Care Paramedic (ICP) response vehicles
Sequentially numbered, opaque, sealed envelopes (SNOSE) for allocation concealment — foil-lined to prevent transillumination and tamper-signed across the seal — stored on each ICP response vehicle
Study-specific case report forms (paper and/or electronic)
A laminated on-scene infographic summarising the post-randomisation algorithm for both arms
Standardised training materials (see "Training" below)

Who delivers the intervention
The intervention is delivered by South Australian Ambulance Service (SAAS) Intensive Care Paramedics (ICPs). ICPs are advanced-practice paramedics qualified to deliver critical care interventions including advanced airway management, vasoactive and antiarrhythmic drug administration, and resuscitation team leadership. SAAS dispatch protocol mandates the attendance of at least one ICP at every cardiac arrest within the Adelaide metropolitan area. Only ICPs who have completed the study-specific training package may recruit, randomise, and deliver the intervention.

Mode of delivery
Face-to-face, individually delivered, in the prehospital out-of-hospital environment at the scene of the cardiac arrest. The intervention is delivered once per eligible patient.

Number of sessions, schedule, intensity
A single intervention episode per participant. The intervention period spans 10 minutes from the point of randomisation, during which up to two 50 mg esmolol doses (4 minutes apart) are administered. Total study-specified intervention time is therefore 10 minutes; no further study-mandated interventions occur after this window.

Location
Wherever an eligible Out of Hospital Cardiac Arrest (OHCA) occurs within the Adelaide metropolitan area served by SAAS Metro North, East, South, and West sectors — typically the patient's home or a public place. The intervention is delivered on-scene; if extrication or transport is required, the intervention continues uninterrupted where operationally feasible.

Tailoring/personalisation
The intervention is delivered to a fixed protocol and is not titrated to individual patient characteristics. The only protocol-permitted variation is the discretionary administration of the second esmolol dose if a patient continues to experience persistent VF/VT cardiac arrest within the 10-minute window, as described above. Concurrent ALS care (e.g. airway choice, mechanical CPR device, fluid administration) remains at the discretion of the treating ICP within SAAS scope of practice.

Training of intervention providers
Prior to recruitment commencement, all participating ICPs across the four metropolitan sub-sites will complete a standardised study education package covering: study rationale, inclusion/exclusion criteria, the randomisation procedure (SNOSE), the intervention and standard-care algorithms, esmolol pharmacology and administration, data collection requirements, and consent/waiver-of-consent processes. Training will include didactic content and simulation-based practice. Pre- and post-training competency assessments will be administered, and clinician self-reported confidence/competence will be measured before and after training.

Adherence/fidelity assessment
Fidelity will be assessed as a primary feasibility outcome by the study team. Indicators include:

Proportion of intervention-arm participants receiving the full bundle (cessation of adrenaline, esmolol dose 1, vector-change defibrillation, and esmolol dose 2 where indicated)
Proportion of standard-care participants in whom no beta-blocker was administered during the prehospital phase
Proportion of recruited participants in whom randomisation was completed at point of care without protocol deviation
Completeness of case report form data at each predefined time point
Qualitative narrative from participating ICPs regarding barriers to recruitment, randomisation, and protocol adherence, captured via retrospective case review and post-case debriefing

The pre-specified progression threshold is greater than or equal to 80% protocol adherence in each arm, averaged across the four sub-sites. Strategies to maintain fidelity include the on-scene infographic, ongoing refresher training, regular feedback to ICP teams on aggregate adherence data, and individual case review with treating clinicians where deviations occur.
Intervention code [1] 334148 0
Treatment: Drugs
Description of the comparator or control
Comparator (Control) treatment- Standard Advanced Life Support (ALS) care ("Standard Care")

Rationale: The comparator arm represents current best-practice prehospital management of persistent VF/VT cardiac arrest as defined by Australian and New Zealand Committee on Resuscitation (ANZCOR) ALS guidelines and South Australian Ambulance Service (SAAS) standard operating procedures. It is the active treatment against which the intervention bundle is compared.

Drug component

International Non-proprietary Name: Adrenaline (epinephrine)
Dose: 1 mg bolus
Schedule: Administered every 4 minutes (i.e. on alternate 2-minute ALS cycles), as per ANZCOR ALS
Mode of administration: Intravenous (IV) or intraosseous (IO) bolus
Duration: Continues throughout the 10-minute study window and beyond, in accordance with standard ALS, for as long as resuscitation continues
Antiarrhythmic: Amiodarone administered per ANZCOR ALS in both arms (this is not a between-arm difference)
No beta-blocking agent of any kind is administered by the prehospital team to participants in this arm during the prehospital phase of care, including after the 10-minute study window. Participants on chronic oral beta-blocker therapy remain eligible; if post-ROSC beta-blockade becomes clinically indicated, the in-hospital team is at liberty to administer it.

Non-drug components

Vector-change defibrillation – Defibrillation pads are repositioned to an anterior–posterior configuration after the three unsuccessful shocks that establish eligibility (if not already in this position). Vector change is delivered in both arms as it represents current ANZCOR-endorsed standard of care for persistent shockable rhythms and is included to maintain protocol equipoise.
Standard ALS continues throughout: high-quality manual or mechanical chest compressions (LUCAS 3 [Stryker] or Corpuls CPR [GS Elektromedizinische Geräte] where available), advanced airway management with waveform capnography, IV/IO access, rhythm checks and defibrillation at standard 2-minute intervals, and any other adjuncts within SAAS standard scope of practice.
Post-window care – If the patient remains in persistent VF/VT 10 minutes after randomisation, the treating team continues care in accordance with ANZCOR ALS and routine SAAS standard operating procedures, which may include transport to hospital. The prohibition on prehospital beta-blocker administration in this arm is maintained for the duration of prehospital care. In-hospital management is at the discretion of the receiving clinical team and is not constrained by the study protocol.

Materials used in comparator delivery

Standard SAAS resuscitation drug pack (including adrenaline and amiodarone) carried on ICP response vehicles
Sequentially numbered, opaque, sealed envelopes (SNOSE) for allocation concealment (identical to the intervention arm)
Study-specific case report forms (paper and/or electronic)
A laminated on-scene infographic summarising the post-randomisation algorithm for both arms
Standardised training materials

Who delivers the comparator
SAAS Intensive Care Paramedics (ICPs) — the same providers, with the same scope of practice and the same study-specific training, as in the intervention arm.
Mode of delivery
Face-to-face, individually delivered, in the prehospital out-of-hospital environment at the scene of the cardiac arrest. Delivered once per eligible patient.
Number of sessions, schedule, intensity
A single resuscitation episode per participant. The study-specified comparator period spans 10 minutes from the point of randomisation, during which up to three 1 mg adrenaline doses may be administered in accordance with ANZCOR ALS timing. ALS continues beyond the 10-minute window for as long as clinically indicated, with the single ongoing study-imposed constraint being the withholding of prehospital beta-blockers.

Location
Identical to the intervention arm — wherever an eligible OHCA occurs within the Adelaide metropolitan area served by SAAS Metro North, East, South, and West sectors.

Tailoring/personalisation
Concurrent ALS care (e.g. airway choice, mechanical CPR device, fluid administration) is at the discretion of the treating ICP within SAAS scope of practice, as is the case in routine non-study cardiac arrest care.

Training of providers
Identical study education package as for the intervention arm (see Intervention field). Training explicitly covers the standard-care algorithm and the prohibition on prehospital beta-blocker administration in this arm.

Adherence/fidelity assessment
Fidelity in the comparator arm will be assessed as part of the primary feasibility outcome. Indicators include:

Proportion of standard-care arm participants in whom no beta-blocker was administered during the prehospital phase
Proportion of standard-care arm participants receiving adrenaline at the protocol-specified frequency
Completeness of case report form data at each predefined time point
Qualitative narrative from participating ICPs regarding barriers to protocol adherence

The pre-specified progression threshold is greater than or equal to 80% protocol adherence, averaged across the four sub-sites.
Control group
Active

Outcomes
Primary outcome [1] 345497 0
Recruitment feasibility: Identification and recruitment of eligible patients with persistent VF/VT in the prehospital environment.
Timepoint [1] 345497 0
Over 2 year study period
Primary outcome [2] 345498 0
Randomisation feasibility: Implementation of randomisation reliably in a time-critical emergency prehospital environment
Timepoint [2] 345498 0
Over 2 year study period
Primary outcome [3] 345499 0
Protocol & training adherence: Delivery of the intervention bundle (esmolol with de-emphasised adrenaline) consistently across SAAS Intensive Care Paramedic teams, alongside training & education package effectiveness
Timepoint [3] 345499 0
Over 2 year study period
Secondary outcome [1] 461916 0
Percentage of enrolled patients who survive to hospital who go on to survive to discharge or 30 days (whichever is sooner)
Timepoint [1] 461916 0
For patients who are enrolled in the trial in the prehospital space and who go on to survive to hospital, data will be collected from point of arrival to hospital to 30 days post recruitment
Secondary outcome [2] 462509 0
Percentage of enrolled patients for whom physiological data (end tidal CO2 and invasive blood pressure) was collected during the study period
Timepoint [2] 462509 0
Baseline only- data collection during intervention window (i.e. from point of enrolment to point of enrolment plus 10 minutes)
Secondary outcome [3] 462511 0
Percentage of enrolled patients that experience return of spontaneous circulation (ROSC) during the intervention period or at any point following the intervention period up to arrival at hospital.
Timepoint [3] 462511 0
Baseline only- from point of enrolment up to time of cessation of resuscitation OR arrival at hospital, whichever is sooner.
Secondary outcome [4] 462512 0
Percentage of enrolled patients who survive to hospital presentation as a percentage of total enrolled patients
Timepoint [4] 462512 0
Baseline only- from point of enrolment up to time of cessation of resuscitation OR arrival at hospital, whichever is sooner.
Secondary outcome [5] 462521 0
Percentage of patients enrolled in the study who have a neurological outcome at 30 days OR hospital discharge (whichever is sooner) defined as favourable (score 0-2) using the modified Rankin scale
Timepoint [5] 462521 0
from point of recruitment to 30 days post recruitment

Eligibility
Key inclusion criteria
Age greater than or equal to 18 years
Experiencing out of hospital cardiac arrest characterised by persistent VF/VT after 3 shocks from any defibrillator.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Visibly pregnant people
Prisoners
Traumatic cardiac arrest
Cardiac arrest secondary to or associated with drowning
Cardiac arrest secondary to or associated with hanging
Patients with a valid DNACPR decision documented

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be achieved using sequentially numbered, opaque, sealed envelopes (SNOSE), prepared in accordance with established best practice,

(Doig GS, Simpson F. Randomization and allocation concealment: a practical guide for researchers. J Crit Care. 2005;20(2):187–91
Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. The Lancet. 2002;359(9306):614–8. )

and consistent with the CONSORT 2010 allocation-concealment standard. Envelopes will be lined with aluminium foil to prevent transillumination, tamper-signed across the seal, stored on each Intensive Care Paramedic response vehicle, and opened only after on-scene eligibility has been confirmed. Given the nature of the intervention, treating clinicians cannot be blinded to allocation; however, the data analysis team will remain blinded to mitigate detection and analytic bias.
Treating prehospital clinicians will not be blinded to the interventions provided in the prehospital setting.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The allocation sequence will be computer-generated by an independent statistician not otherwise involved in recruitment or clinical delivery, using permuted blocks to maintain approximate balance throughout enrolment. Randomisation will be stratified by SAAS metropolitan sub-site (North, East, South, West) to account for operational variability between sectors and to ensure balanced allocation within each, with a target of ten participants per sub-site
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Efficacy
Statistical methods / analysis
Analysis will be primarily descriptive, focusing on feasibility outcomes. Summary statistics will be used to report recruitment, adherence, and data completeness. Exploratory comparisons between groups will use appropriate statistical tests (e.g. t-test, Mann–Whitney U, chi-squared), recognising that the study is not powered to detect efficacy differences at the feasiblity stage

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 321930 0
Self funded/Unfunded
Name [1] 321930 0
Country [1] 321930 0
Primary sponsor type
Government body
Name
South Australian Ambulance Service
Address
Country
Australia
Secondary sponsor category [1] 324799 0
None
Name [1] 324799 0
Address [1] 324799 0
Country [1] 324799 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320466 0
Southern Adelaide Clinical Human Research Ethics Committee
Ethics committee address [1] 320466 0
Ethics committee country [1] 320466 0
Australia
Date submitted for ethics approval [1] 320466 0
15/05/2026
Approval date [1] 320466 0
Ethics approval number [1] 320466 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150562 0
Dr James Macpherson Wood
Address 150562 0
SAAS MedSTAR, Sir Reginald Ansett Drive, Adelaide Airport, SA 5950
Country 150562 0
Australia
Phone 150562 0
+61 406829909
Fax 150562 0
Email 150562 0
Contact person for public queries
Name 150563 0
James Macpherson Wood
Address 150563 0
SAAS MedSTAR, Sir Reginald Ansett Drive, Adelaide Airport, SA 5950
Country 150563 0
Australia
Phone 150563 0
+61 406829909
Fax 150563 0
Email 150563 0
Contact person for scientific queries
Name 150564 0
James Macpherson Wood
Address 150564 0
SAAS MedSTAR, Sir Reginald Ansett Drive, Adelaide Airport, SA 5950
Country 150564 0
Australia
Phone 150564 0
+61 406829909
Fax 150564 0
Email 150564 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Due to the structure of our consent process in critical illness, we are unable to consent patients for this.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.